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Abstract. The use of 5-aminolevulinic acid and its esters to
induce endogenous porphyrins for the purpose of detection of
epithelial cancers is being studied extensively in many centr.es
around the world. The challenge is to prepare an efficacious
formulation for the purpose of cancer detection. Photodynamic
diagnosis of cancer using 5-aminolevulinic acid (ALA) and
its ester derivatives is being actively investigated. In this
study, we compared ALA with ALA methyl ester (AME)
derivative in terms of PplX fluorescence intensity in in vitro
and in vivo systems of bladder carcinoma. For the in vivo
system consisting of RT112 xenografts, the modes of drug
administration compared were intravenous administration and
topical application. The Karl Storz fluorescence endoscopy
system was used to obtain macroscopic fluorescence images.
The macroscopic images were further analysed for fluorescence
intensity distribution. For the intravenous administration, over
all time points studied (1, 3, 6 h), AME-PpIX fluorescence
was lower than ALA-PplX fluorescence and was cleared at
a faster rate than the ALA-PplX when administered intravenously. Topical application with two different polymers,
Gantrez and Polyvinyl pyrrolidone (PVP) which are fast
releasing polymers was found to be comparable in inducing
PpIX fluorescence. Topical AME-PplX fluorescence was
found to be comparable with ALA-PpIX fluorescence. The
results of this study suggest that the AME can also be used as
a good diagnostic agent.
Introduction
Bladder cancer is one of the most prevalent malignant
diseases in the world (1). In Singapore, it is the 9th most
common type of malignancy. It has been reported that 75-80%
of malignancies is superficial in nature and the chances of
recurrence after first treatment in these malignancies are 70%
(2). Early diagnosis of dysplasia and urothelial tumours plays
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an important role in prognosis of the disease. The use of endogenous protoporphyrin IX (PplX) as a photosensitizer to
diagnose certain superficial cancers is under extensive study
in many centres around the world. This is because it is a noninvasive technique. Endogenous PpIX can be induced by the
administration of excess 5-aminolevlinic acid (ALA) or its
esterified analogues. ALA is a precursor in the heme biosynthetic pathway of nucleated cells. It is metabolized by
certain endogenous enzymes to produce PpIX. PpIX is a photosensitive intermediate by-product in the heme biosynthetic
pathway (3). Along with PpIX there are other porphyrin
species such as heptaporphyrin, coproprophyrin, and uropophyrin (13,14). Survival of mammalian cells is crucially
dependent upon the biosynthesis and metabolism of porphyrins
(4). PpIX being the immediate precursor of heme will also be
synthesized in equal amounts. However, a tight feedback loop
control ensures that only a scarce amount of PpIX is left at
any one time (5). Accumulation of the endogenous porphyrins
only happens under abnormal conditions such as in malignant
or pre-malignant cell transformation. PplX preferentially
accumulates in tumour cells due to changes in th.e activity of
two main enzymes, porphobilinogen deaminase (PBG) and
ferrochelatase (FC) (6-8). In tumour cells, while the activity
of PBG is increased, the activity of FC is decreased resulting
in the build up of PpIX. In normal cells, FC catalyses the
conversion of photosensitive PpIX to heme, which is not
photosensitive. It chelates the Fe2+ into the porphyrin ring
structure. The administration of excess exogenous ALA or
various esterified analogues of ALA can also induce the excess
production of PpIX (topically or intravenously). While ALA
is hydrophilic, which is a limitation as it restricts its penetration
through cellular membranes; its ester derivatives have been
developed to be of increased lipophilicity. In our study we
have compared AME with ALA. Increased transmembrane
access into the cell, large amounts of ALA can be generated
inside the cell due to the abundance of non-specific intracellular
esterases in majority of the cells (15). Different esterified
analogues behave differently in cells. The cytotoxicity and
phototoxicity vary among these esters. Though the esters
enter the cell at a faster rate, they need to be cleaved in order
to function in the heme biosynthetic pathway. However, the
mechanism by which the ALA enters the cells is transported
across the membrane via peptide transporters and the transport
is electrogenic and coupled to H+ transport (6,16).
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PpIX is a well-known photosensitizer that yields sufficient
singlet oxygen when activated by light of appropriate wavelength and intensity. ALA is already in use in many centres for
photodynamic diagnosis ~PDD) and photodynamic therapy
(PDT) in various superficial diseases such as actinic keratosis,
basal cell carcinoma and squamous cell carcinoma. ALA
induced PpIX is also highly fluorescent. Upon activation with
blue/violet light, PpIX fluoresces in red. ALA is also used for
the detection of neoplastic urothelial lesions, early stage lung
cancer, cervical dysplasia and laryngeal neoplasm. Most
studies have been done on applications to the skin. It was
observed that the skin overlaying the tumours, which looks
normal, constitutes a much lower barrier for ALA penetration
than the skin overlaying healthy tissues. It was also found
that the ALA induces more PpIX fluorescence than certain of
its esters do. Systemic uptake is also reported to be higher
resulting in high accumulation of PpIX in other vital organs
such as the liver, gut and skin. These studies were compared
with intravenous or intraperitoneal administrations of ALA
(9-I2). AME-PDT is currently being studied in basal cell
carcinomas in humans. Very few studies have reported the
use of AME for cancer detection due to the seemingly low
production of PplX in vivo.
One of the aims of this study was to compare the uptake
and retention kinetic of ALA and AME in bladder cancer
cells in vitro and in vivo. We went on to conduct this study by
using topical applications of ALA and AME and intravenous
administration. With the use of macroscopic fluorescence
imaging of endogenous PpIX, the optimal selectivity between
tumour and normal regions was determined. For the topical
application two fast acting polymers Gantrez and Polyvinyl
pyrrolidone (PVP) were compared, these are currently being
studied for rapid drug delivery and transdermal films. Gantrez
is a synthetic copolymer of methylvinyl ether and maleic
anhydride. It has several applications such as transdermal
films and carriers for mucosa! applications of the oral cavity.
PVP is also being extensively studied in area of transdermal
films (I7).
Materials and methods
In vitro cellular uptake studies. RT112 is a grade II (poorly
differentiated) human bladder carcinoma cell line (ATCC).
It was a kind gift from Clinical Research Centre, National
University of Singapore. The cells were grown in culture
medium RPMI I640 supplemented with 10% fetal bovine
serum (FBS; Hyclone, Logan, UT), IX L-glutamine, 100 units/
ml penicillin and streptomycin (Gibco) and IX sodium
pyruvate in an atmosphere of 5% C0 2 at 37°C. Confluent
cells were trypsinized with 0.05% Trypsin-EDTA (Gibco)
and seeded onto 100 mm petri dishes (l.5xl0 6 cells/dish)
and left to settle and attach overnight. The culture medium
was removed and the cells were washed twice with IX PBS.
The petri dishes were divided into two groups. They were
incubated with I5 mM ALA and I5 mM AME in culture
medium without serum for 30 min. The cells were then washed
with IX PBS. Fresh medium without serum was added to the
dishes and incubated at 37°C with 5% C0 2 for I, 3, 6, 9 and
24 h. At each time point the cells were washed with IX PBS,
scraped and incubated in perchloric acid and methanol mixture

(I:I) for I5 min. ALA and AME induced PpIX was detected
using the spectrofluorophotometer RF-530I PC (Shimadzu).
Excitation was set at 400 nm and the emission spectrum range
was set at 500 to 700 nm.
Tumour model. RTI I2 cells were grown in culture medium
as for the in vitro studies. Once confluent they were washed
with IX phosphate buffered saline and trypsinized with 0.05%
Trypsin-EDTA (Gibco). The cells were then re-suspended
in IX Hanks balanced salt solution. Male Balb/c nude mice,
6-8 weeks old, about 20-25 g were obtained from Animal
Resource Centre of Australia. The trypsinized cells (l.5xIQ6)
were implanted subcutaneously into the flanks of the nude
mice. The mice were housed in micro-isolator cages (5 per
cage) fed with filtered air through air vents. Their food, water
and bedding were sterilized. The tumour was allowed to grow
over the next 7-10 days to a size of 5-8 mm in diameter.

ALA/AME topical applications. For the Gantrez topical 1
application, ALA/AME were dissolved in poly (methyl vinyl'1
ether/maleic anhydride (Gantrez, ISP, USA)/poly (meth)'
acrylates (Eudragit, Rohm Pharma, Germany)/alcohol
solution. For the PVP, ALA and AME were dissolved in.
polyvinyl-pyrrolidone (Plasdone, ISP, USA)/alcohol solution.
A concentration of 2.5 mg/cm 2 of ALA and AME for both
formulations of topical application was prepared. The solutio
was then poured onto a calculated area of polythene sheets
and air dried to form films. The films were cut into 1.5 cm
pieces and sealed in bags and stored for further use. Botli
formulations have muco-adhesive properties.
·
.~

Animal experiments. Six groups of balb/c nude mice wer
used. Group I was used for the intravenous administration o
ALA. Group 2 was used for intravenous administration o
AME. Group 3 was used for Gantrez ALA topical application
Group 4 was used for Gantrez AME topical application. Grau
5 was used for PVP ALA topical application. Finally group
was used for (PVP) AME topical application. For topica
application, 5 mice per group were used. The nude mic
were anaesthetized with a cocktail of Hypnorm (0.3 I5 mg/
fentanyl citrate and 10 mg/ml flaunisone, Janssen), Dormic
(5 mg/ml midazolam HCl, David Bull Laboratories) an
deionised water (I:I:2). The skin overlaying the tumour wa
carefully removed to expose the tumour. Extreme care wa
taken to minimize bleeding as this can interfere with th
imaging procedure. A white light image of the tumour wa
obtained using the Karl Storz fluorescence endoscopy syste
(FES). This is to help later in identifying the tumour and it
margins when comparing with the fluorescence image. Th
films were then applied on the tumour making sure that th.
patch covered the tumour well and also part of the norm '
tissue surrounding the tumour. For the muco-adhesive films
the patch was applied for 30 min and then removed. The are
was rinsed well with 70% alcohol to remove any residual AL
The tumour was imaged at different time points, post topica
application, by the FES using filtered blue light at 460 nm.
Intravenous administration. ALA/AME was dissolved i
deionized water and the pH was adjusted to 6.5. The mic
were administered with a dose of 250 mg/kg-body weight b
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Figure 1. PpIX fluorescence of ALA and AME treated RTI 12 cells.
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~
tail vein injections. Five animals were used for each time
point. They were then kept in darkness. The mice were
imaged at various time points, such as 1, 3 and 6 h. The skin
overlaying the tumour was removed and the tumours were
imaged using the FES. The mice were then sacrificed, the
tumours were removed and snap frozen in liquid nitrogen and
stored at -80°C for further analysis.
Instrumentation. The system consists of a fluorescence
detection unit, an illumination console, a video displaying
and recording unit, and a computing system for image
acquisition, display and processing. A 100 W xenon arc lamp
(D-Light AF system, Karl Storz, Germany) is used for the
white light illumination and the PpIX fluorescence excitation
when filtered by a band pass filter (370-450 nm). The
excitation power of the blue light at the endoscope tip is
approximately 50 mw. Both of the light illumination and
the observation of the tissue targeted are achieved via a
modified endoscope equipped with a long pass (LP) filter
(cut-off wavelength at 470 nm). The white light and ALA
fluorescence imaging were achieved by a 3-chip colour CCD
video camera (Tricam SL_PDD, Karl Storz, Germany)
connected to the modified endoscope.
Image analysis. The images thus obtained were analyzed
using the image analysis software, Microlmage 4.0. Images
obtained in blue light needed to be further processed to obtain
normalized fluorescence intensity images. The processing
involves cpntrast enhancement of the original image. This is
followed by hue extraction where one extracts the fluorescence
colour (red) that is needed. Following hue extraction, the
thresholding and segmentation of the area of interest (AOI),
which is the tumour in this case, was carried out. This gives
us the red-black image. From this we obtained the relative
intensity distribution over the tumour and the normal regions.
Finally, the normalised intensity image, which is a ratio of the
tumour fluorescence to the normal (blue) background, was
obtained.
Statistical analysis. Statistical analysis was done using the
SPSS 10.0 statistical package for Windows. Analysis was
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Figure 2. (A), Normalized fluorescence intensity of tumour vs. normal as a
function of time for IV ALA. (B), Normalized fluorescence intensity of
tumour vs. normal as a function of time for IV AME.
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Figure 3. ALA induced PpIX fluorescence for Gantrez and PVP topical
application.

done by comparing means (ANOVA). The mean difference
was found to be statistically significant (p<0.05).
Results

Using the spectrofluorophotometer, we measured the
fluorescence intensity of ALA and AME induced PpIX in
cells over time. Fig. 1 shows the ALA and AME induced
PpIX fluorescence intensity of RTI 12 cells over time in vitro.
While ALA induced PpIX fluorescence decreased after 9 h
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Figure 4. AME induced PpIX fluorescence for Gantrez and PVP topical
application.

due to the PpIX being converted to heme, AME induced PpIX
fluorescence continued to increase and peaked at around 24 h.
This could be due to the fact that AME has to be cleaved before
it enters the heme synthesis pathway. Fig. 2 shows the PpIX
fluorescence intensity of RT112 tumours when administered
with intravenous ALA and AME 2SO mg/kg respectively. It
was observed that the tumour to normal differential was
significantly high from the earliest time point 1 to 6 h. On the
other hand AME induced PpIX fluorescence in the tumour
was found to be high at 1 h but started to decline thereafter.
By 6 h the tumour to normal differential was low. Fig. 3
shows the PpIX fluorescence intensity of RT112 tumours
when Gantrez ALA and PVP ALA were applied and imaged
at the different time points. It was observed that the tumour
to normal differential was increased significantly by 3 h and
continued to increase even at 6 h. Fig. 4 shows the PpIX
fluorescence intensity of RTl 12 tumours when Gantrez AME
and PVP AME were applied and imaged at the different time
points. This pattern was found to be similar to that of topical
ALA applications. The only difference was that the AME
induced PpIX fluorescence intensity seemed to be slightly
higher especially at 6 h. Tumour to normal fluorescence ratio
(TIN ratio) was calculated to better appreciate the fluorescence
pattern found in the IV administration and the topical
applications of the two drugs. Since both topical applications
followed the same pattern, only one was chosen to be
compared. The TIN ratio of topical PVP ALA and AME
induced PpIX increased as a function of time between 1 to 6 h
as seen in Fig. SA. However, the TIN ratio ofIV AME induced
PpIX fluorescence decreased as a function of time between 1
to 6 h while the IV ALA induced PpIX fluorescence increased
as seen in Fig. SB. Fig. 6 shows a series of fluorescence images
of different mice taken using the FES at different time points.
The fluorescence pattern for IV and topical application is
clearly visible. Fig. 6A-C denotes ALA IV; Fig. 6D and E
denotes AME IV; Fig. 6G and H denotes PVP ALA; and
Fig. 6J-L denotes PVP AME.

Figure 5. (A), TIN fluorescence ratio of ALA and AME PVP induced PpIX.
(B), TIN fluorescence ratio of ALA and AME IV induced PpIX.

Discussion

This study was done to investigate uptake and retention
pharmacokinetics of ALA and AME in bladder cells in vitro.
This pharmacokinetic profile in vitro was used to better.
understand the difference between the in vitro and in vivo.
Subsequently this tumour cell line was xenografted in nude,
mice and the uptake kinetics studied in vivo. Then we wen
on to compare the modes of administration of the drug. Intra-·
venous administration of ALA for endogenous porphyrin based
PDD and PDT, has been the normal mode of administration.
AME is still being studied in many centres based on th
rationale that esters are transported into cells at a faster rate.
However, there are no in vivo studies of the intravenous'
administration of AME in bladder cancer. In our investigations,
we removed the skin overlaying the tumour to mimic epithelial condition where the drug does not have to trave
through the stratum corneum, sebacious glands, dermal papill
etc. We detected that the intravenous ALA and AM .
administration not only gives high fluorescence of tumour'
but also that of normal distal organs such as the skin, normal
1
liver and intestines from as early as 1 h post ALA and AME
administration, which is due to considerable amounts o
circulating ALA inducing local PpIX. However, it was foun
that the fluorescence intensity of tumour was reasonably high,

INTERNATIONALJOURNALOFONCOLOGY 22: 313-318, 2003

lbr

3br

317

6br

Figure 6. Fluorescence images captured with the FES. (A-C), ALA IV; (D-F), AME IV; (G-I), PVP ALA application; (J-L), PVP AME application. The tumour
has been imaged with the surrounding tissue and skin.

from 1 to 6 h post intravenous administration compared to
adjacent normal tissue. On the contrary, the topical applications
did not produce high fluorescence for either the tumour or
normal at 1 h post application. Significant difference between
tumour and normal was evident only at the 3-h time point.
It is noteworthy that the fluorescence of normal tissue was
lower than that of the normal tissue in intravenous
application at the same time point. At 6 h the difference
between tumour and normal is 4.4 times greater and statistically
significant (p<0.05). AME behaves differently in the in vitro
system. PpIX induced by it in the cells is far more than
produced by ALA in the cells. This is not the case in the in
vivo animal study that received the AME IV. The difference
observed in the in vitro and the IV in vivo systems may be
attributed to drug metabolism in the in vivo system that
reduced the drug availability of the parent compound AME
to produce PpIX. However, in an in vivo system with the
topical application of AME (which mimics the in vitro system)
allows for the longer retention of drug, which is bound to the
cell membrane. This discrepancy has been described in other
studies (15,18,19). These studies suggest that ALA derivatives
With many carbon atoms which are highly lipid soluble might

not be converted to ALA by enzymes because such ALA
would accumulate at the cell membranes. and not diffuse into
the cell. The properties of ALA would determine which ALA
derivative induces high level of PpIX. The other variable that
has an effect on the PpIX production is the availability of
oxygen. In in vitro studies the oxygen pressure is sufficient
for the conversion of ALA derivatives into PpIX. Whereas
in an in vivo system where the oxygen tension is low, the
build up of PpIX is expected to be lower (19). When adjacent
skin was analysed for PpIX fluorescence using the topical
application, it was found that the AME induced less cutaneous
sensitivity when compared to ALA.
Thus, there are merits for ALA and AME delivery via
topical applications. This delivery system may take many
forms such as rinses, gels or creams, which have to be
constituted extemporaneously when needed due to instability
of ALA. Films prepared for this study can be made and stored
in an airtight container at room temperature for 3 to 6
months. These topical applications also have muco-adhesive
properties and can be good candidates for use in the oral
cavity PDD and PDT. However, oral rinses require the
patient to continuously rinse for 20 min. Hence oral rinses
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are not practical for routine clinical use. Also the contact
time for ALA on oral tissue is short with the use of an oral
rinse.
Despite the expected differences in the availability of ALA
in the Gantrez application and PVP application, their in vivo
performances did not show significant differences. This
indicates that the rate-limiting step of ALA delivery to the
tumour tissue was the transdermal transport of the hydrophilic
ALA compound. However this seems to be tumour dependent
(13).

Our study concludes that the amount of PpIX produced,
as a function of time (1-6 h) in the in vivo system does not
correspond to the in vitro system. While topical applications
will be good for accessible tumours, as the TIN differential is
significant by 3 h (p>0.05), intravenous administration also
has its advantages because high tumour to normal differential
is achieved at a shorter duration for both ALA and AME.
Between the intravenous administration and the topical
application, the difference lies in the fact that there is low
systemic uptake in the topical application. Therefore the mode
of ALA and AME administration will play an important role
in the specific application in cancer diagnosis of the bladder.
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